On BMS’ Plea, Delhi Court Nixes Hetero’s Dasatinib Application; Directs India’s Drug Controller To Examine Patent Violations

MUMBAI - In a decision that could have a far-reaching impact on drug patent cases in India, the Delhi High Court has directed the Drug Controller General of India to monitor for patent infringements by any party while a drug's approval application is scrutinized